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 Introduction 
 Identification and treatment of chronic kidney disease 
(CKD) is a major concern  [1, 2] . Early diagnosis of pro-
gressive kidney disease is of the highest importance. Most 
doctors know the limitations of serum creatinine for the 
detection of early CKD  [3] . Serum creatinine concentra-
tion varies with the kidney function, and is also influ-
enced by ‘non-nephrological’ factors such as sex, race, age 
and muscular mass. Due to these limitations, one can es-
timate glomerular filtration rate (GFR) with creatinine-
based formulas that account for anthropometrical and 
biological variation  [1] . The two best known equations 
are the equation published in this journal by Cockcroft 
and Gault in 1976  [4] and the most recent equation pub-
lished by Levey et al.  [5] in 1999 using the data from the 
Modification of Diet in Renal Disease (MDRD) study ( ta-
ble 1 ).  Table 2 compares the methodology and the popu-
lation of both studies. The MDRD study estimates GFR 
in comparison to its measurement by the iothalamate 
method whereas the Cockcroft equation estimates cre-
atinine clearance, which is not identical to the GFR, sen-
su stricto  [1] . The Cockcroft-Gault population was nearly 
all male. Another fundamental difference between these 
two formulas is the mean GFR of the population from 
which they have been built. These are, respectively, 39.8 
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 Abstract 
 Regarding the prevalence of chronic kidney disease in the 
population, estimation of glomerular filtration rate is of im-
portance. Creatinine-based formulas are thus useful as the 
first step of a prevention strategy. Several creatinine-based 
formulas have been published. Among these, the Cockcroft-
Gault formula and the Modification of Diet in Renal Disease 
(MDRD) study equation are the most used by physicians. The 
latter may be automatically reported by laboratories and has 
thus great success. However, these formulas have limita-
tions. First, the MDRD formulas are not applicable to all pop-
ulations, notably the healthy one and the patients with ab-
normal weight (anorectic or obese). Second, we evoke the 
limitations in the precision of the formulas linked to analyti-
cal aspects. Indeed, these analytical limitations remain sig-
nificant even if they are improved by creatinine standardiza-
tion. Lastly, we briefly mention the potential impact of these 
limitations on the epidemiology and the staging of chronic 
kidney disease.  Copyright © 2008 S. Karger AG, Basel 
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ml/min/1.73 m 2 in the MDRD study versus 72.8 ml/min 
in the Cockcroft-Gault cohort.
 The MDRD estimated GFR (eGFR) can be reported by 
clinical laboratories because it requires only knowledge 
of a person’s serum creatinine, age, and sex, the race be-
ing interpreted by the clinician. Different correction fac-
tors are applied to the MDRD results according to the 
ethnicity of the patient (summarized in  table 1 ). These 
factors could increase the accuracy of the MDRD study 
formulae, contrary to the Cockcroft equation for which 
no ethnic corrections have been described  [6–8].  It is thus 
not surprising that this equation is used more and more. 
The simplicity of the Cockcroft equation is thus sur-
passed. However, the success story of the MDRD study 
equation does not make it invincible.
 MDRD Study Equation
Good for Everybody? 
 As mentioned, the MDRD study equation was built 
from a CKD population  [5] . It is well-known that the re-
lationship between GFR and creatinine is not the same in 
CKD and healthy subjects  [3] . Indeed, the MDRD for-
mula may underestimate the true GFR in healthy sub-
jects. There is substantial imprecision for the result of the 
eGFR compared to its measured value, when the mea-
sured value is  6 60 ml/min/1.73m 2  [9, 10] .
 To these mis-estimates two obvious situations can be 
added in which formula-based estimates of the GFR are 
futile, even if still commonly reported on laboratory re-
sult reports. These are in the patients with acute kidney 
injury and changing kidney function, and in the patients 
on chronic dialysis. Those with acute kidney injury are 
not in the steady state, and those on chronic dialysis have 
no GFR of their own.
 Where Is the Body Weight? 
 The Cockcroft-Gault equation uses the weight as a 
variable  [4] . This is logical because the serum creatinine 
concentration varies with muscular mass. But weight is 
only an indirect estimation of the muscular mass. Inac-
curacies in the equation thus occur when it is applied to 
obese or cachectic subjects. Several authors have shown 
the inaccuracy of the Cockcroft formula in these two 
populations  [11, 12] . The Cockcroft formula could also be 
misleading when eGFR is longitudinally followed in an 
obese patient on a weight-loss diet. If the patient loses fat 
weight, the eGFR by Cockcroft will decrease, probably 
without a large decrease of true GFR. One may wonder 
why the weight variable does not appear in the MDRD 
study equation. This is explained by the fact that the 
MDRD equation indexes its GFR determination by the 
body surface area (BSA), and BSA takes into account the 
body height and weight. However, indexing GFR for BSA 
is questionable as we have already shown  [13] . Indeed, 
indexing GFR for BSA implies that the relationship be-
tween GFR and BSA is linear and that this relationship 
disappears when indexed GFR is used. This is not true. 
Indexing GFR will have only minimal impact on the ab-
solute results in the population with normal BMI. The 
impact of indexing will be high in obese patients  [13] . The 
mean weight of the original MDRD population was 79.6 
 8 16.8 kg. Most of the patients in the MDRD study were 
neither severely obese nor cachectic. Independently of 
the limitations linked to the BSA, Verhave et al.  [12] have 
shown that the MDRD study equation underestimates 
Table 1. MDRD study equations and Cockcroft equation com-
monly used for GFR estimation
Cockcroft and Gault
4-Variable MDRD study equation
GFR (ml/min/1.73 m2) =




4-Variable MDRD study equation (IDMS traceable)
GFR (ml/min/1.73 m2) = 
175 ! SCr (mg/dl)–1.154 ! age–0.203 ! 0.742 (if woman)






140 age weight kg
GFR (ml/min) 0 85 if woman




Table 2. Comparison of methodology between the MDRD and 
the Cockcroft study
Cockcroft MDRD
Population and reference Canada 1976 [4] USA 1999 [5]
Sample 249 1,628
Mean GFR 73 ml/min 40 ml/min/
1.73 m2
Reference method Creatinine clearance Iothalamate
% women 4 40
% black unknown 12
Mean weight 72 79.6
BSA indexation no yes
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measured GFR in obese patients by about 10 ml/min. The 
main limitation of this study is linked to the fact that 
most of the subjects had normal GFR and/or creatinine 
values  [14] . We maintain that the use of formula-based 
estimates of the GFR is imprecise in obese and in under-
weight subjects, so that formulas are not suitable to search 
for CKD in these subjects, despite their possible predis-
position to kidney disease.
 Analytical Limitation 
 Due to the exponential relation of the serum creati-
nine to the GFR, a small change in low creatinine values 
will have great impact on the GFR. For example, if a pa-
tient’s creatinine increases from 0.6 to 1.2 mg/dl, this 
means that he has lost half of his initial GFR. However, if 
the creatinine rises from 3 to 3.6 mg/dl in a patient with 
the same anthropometrical data, the loss of GFR is con-
siderably smaller. Thus, close-to-normal and normal se-
rum creatinine values require attention.
 Calibration 
 In 2002, Coresh et al.  [15] illustrated the impact of dif-
ferences in creatinine calibration on the GFR estimation. 
In the NHANES study, the serum creatinine was mea-
sured with the kinetic Jaffé method by the Roche assay on 
the Hitachi 737 machine, whereas in the MDRD study, 
the serum creatinine was measured with the Beckman 
method on the CX3 machine. Results of the serum cre-
atinine measurement were systematically 0.23 mg/dl 
higher with the Hitachi method. For a 60-year-old white 
man with a Beckman serum creatinine of 1 mg/dl, the 
eGFR is 110 ml/min/1.73 m 2 . The serum creatinine of the 
same patient will be 1.23 mg/dl on the Hitachi apparatus, 
which by the MDRD formula will give an eGFR of 81 ml/
min/1.73 m 2 . Further, and due to the exponential relation 
between GFR and creatinine, the impact of the differenc-
es of calibration will be greater for lower serum creatinine 
concentrations. The same difference in calibration will 
induce a difference of only 6 ml/min/1.73 m 2 in the eGFR 
for the same patient if his serum creatinine was 2 mg/dl. 
Others have confirmed the potential impact on the eGFR 
of the differences in creatinine calibration  [16] .
 IDMS-Traceable Creatinine 
 The only way to overcome the potential bias linked to 
the calibration of creatinine is to calibrate the creatinine 
measurement against an absolute standard  [17] . This 
standard does exist, and it is the measurement of creati-
nine by isotope dilution mass spectrometry (IDMS). 
Roche was the first to recalibrate the Jaffé and enzymat-
ic methods to IDMS. Global calibration by other manu-
facturers is ongoing. Levey et al.  [18, 19] have modified 
the MDRD formula based on these calibrations. In fact, 
for serum creatinine values traceable to the IDMS result, 
the factor 186 becomes 175. Nevertheless, the way this 
calibration has been obtained is not free from criticism. 
First, the authors have modified their equation after hav-
ing recalibrated their Jaffé creatinine (Beckman CX3) to 
an enzymatic method (Roche Diagnostic) which has 
been calibrated with the IDMS reference method ( fig. 1 ) 
 [18] . Through their calibrations, the authors have deleted 
the different intercepts because they were not statistical-
ly significant. This is questionable. In fact, even if the 
intercept between Roche enzymatic and IDMS is not sig-
nificant and even if the intercept between Roche enzy-
matic and Beckman CX3 is not significant, this does not 
necessarily imply that the intercept is not different for 
the regression of the IDMS versus the Beckman creati-
nine data! Indeed, Vickery et al.  [20] have also measured 
the direct relation between creatinine measured by IDMS 
and Beckman CX3. These authors found a slope of 0.99 
and an intercept of –0.18 mg/dl which is not negligible.
 The second criticism regarding the IDMS calibration 
concerns the calibration curve between the Beckman 
CX3 creatinine and the Roche enzymatic creatinine 
( fig. 2 ). The calibration curve has been obtained on 40 
reference sera with creatinine values between 0.5 and 
5 mg/dl. From our point of view, the range of creatinine 
used for the calibration appears too large because, once 
again, calibration effect on the MDRD study results are 
only relevant in the lower values of creatinine (0.5–2 mg/
dl). Within this specific range, the slope appears closer to 
1, and not to 0.906 if higher values are included  [21] . Ac-
cordingly, in a study concerning the creatinine calibra-
tion of the NHANES creatinine values, Selvin et al.  [22] 
showed a slope of 1 between creatinine values measured 













Roche = 0.906 ·
CX3 (2005)
n = 40
 Fig. 1. Steps and results of calibration of the MDRD study samples 
to creatinine reference materials [reproduced with permission 
from 18]. 
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fé method used in NHANES 2001–2002 and 2003–2004 
studies. In Selvin’s study, mean creatinine values used for 
calibration are in the important ‘low’ range (0.982 and 
0.977 mg/dl). When one restricts the results of calibration 
between the Beckman Jaffé and Roche enzymatic creati-
nine determinations to the range of creatinine lower than 
2 mg/dl, the regression coefficient between the two meth-
ods is close to 1. The factor 175 may be too low. The true 
factor should be closer than 186. The new choice of the 
factor 175 may contribute to the underestimation of eGFR 
by the thus modified MDRD study equation and to the 
overestimation of CKD  [21, 23] .
 Concepts of Critical Difference 
 Even if we have criticized the way the new IDMS-
traceable equation has been elaborated, we totally agree 
with the need for standardization of the methods of cre-
atinine measurement. However, even when this harmo-
nization will be obtained, all limitations of the creati-
nine-based equations will not disappear. One should 
know the concept of critical difference, which is funda-
mental for biological variables used for ongoing care of 
patients, as is the serum creatinine  [24] . The critical dif-
ference can be defined as the smallest change in results 
which is not due to chance. It is dependent of the ana-
lytical coefficient of variation CV a and the intra-individ-
ual (or biological CV) coefficient of variation (CV i ). In 
laboratories using Jaffé methods for creatinine measure-
ment, CV a for low creatinine values is 5.5%. The intra-in-
dividual coefficient of variation (CV i ) for creatinine is 
4.3%. The critical difference for serum creatinine (= 1.414 
 ! 1.96  ! (CV a2 + CV i2 ) 0.5 ) is thus 19%. A creatinine val-
ue of 1 mg/dl is thus, from an analytical point of view, not 
different from 1.19 or 0.81 mg/dl. When the two latter 
values are used in the MDRD equation (for a white man 
of 60 years), the results are 66 and 103 ml/min/1.73 m 2 , 
respectively, while the eGFR for a serum creatinine of
1 mg/dl would be 81 ml/min/1.73 m 2 . The absolute dif-
ferences between the lower and upper limit eGFRs and 
the eGFR value for a serum creatinine of 1 mg/dl are 15 
and 22 ml/min/1.73 m 2 , respectively. Because the CV a ris-
es with decreasing creatinine values, the critical differ-
ence of creatinine is still higher for serum creatinine val-
ues below 1 mg/dl. Potential differences in creatinine-
based formulae which are merely due to the analytical 
‘error’ of measurement are thus not trivial.
 The critical difference can be decreased with better 
CV a , but a lot of improvement seems difficult to obtain 
with the actual creatinine measurement. If a CV a of 2% 
can be reached, notably with the enzymatic methods, the 
biological variation of creatinine is unchanged. With en-
zymatic methods, then, the critical difference could de-
crease to 13%, but variability of eGFR will remain. Using 
the numbers of the preceding example, these will be 14 
and 11 ml/min/1.73 m 2 , respectively. To repeat, in normal 
creatinine ranges, small changes in creatinine concentra-
tions have considerable consequences in GFR estimation 
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 Fig. 2. Roche enzymatic versus Beckman assays using calibration panel.  a Intercept set to zero was not signifi-
cant; slope 0.906, r 2 = 0.9994.  b Bland-Altman plot [reproduced with permission from 18]. 
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 Other Limitations of the MDRD Study Equation
Impact on the CKD Classification 
 The classification of CKD was proposed in 2002 by the 
K/DOQI (Kidney Diseases Outcomes and Quality Initia-
tive) and KDIGO (Kidney Disease Improving Global Out-
comes) ( table 3 )  [1] . The levels of GFR separating the dif-
ferent stages are much discussed  [26] . That a subject with 
an eGFR  ! 60 ml/min/1.73 m 2 always has true disease is 
questionable. This is especially true for older people be-
cause there is a natural decline in GFR with advancing age. 
The question of the ‘normal range’ of the GFR is still not 
fully resolved, as has been very elegantly shown by Glassock 
 [26] in a recent editorial. We have illustrated the analytical 
limitations of creatinine that cause an imprecision of the 
MDRD study equation in the high values of GFR. These 
limitations are relevant to GFR estimation in the 60 ml/
min/1.73 m 2 range and all the more for higher ranges of 
eGFR. As we have shown, and even if traceability of cre-
atinine and enzymatic methods are clear improvements, 
the precision in this range of GFR remains insufficient. 
This is acknowledged by Levey and colleagues  [17] who 
recommend laboratories not to report the absolute values 
of the MDRD equation for results  1 60 ml/min/1.73 m 2 , 
but simply to state that they are  1 60 ml/min/1.73 m 2 . We 
extend this opinion to further state that to differentiate 
stage 1 CKD from stage 2 is unhelpful in clinical daily 
practice and should be abandoned. This has been also sug-
gested by other authors  [25, 27, 28] and is also stated in the 
Australian guidelines (CARI guidelines)  [29] .
 Impact on the Epidemiology 
 Because the MDRD equation overestimates GFR, this 
equation will overestimate CKD prevalence in epidemio-
logical studies  [2] . For example, that 10% of the general 
population has true CKD is questionable  [23, 26] . It re-
mains possible that in the absence of progressive kidney 
disease, levels of GFR in the 60- to 90-ml/min range may 
carry cardiovascular risk, but this, too, is debatable, as is 
the entirely speculative effect of improving such levels of 
kidney function on that associated risk.
 MDRD Study Equation in CKD Patients: An Estimate 
That Is Not Magic 
 In several studies, the MDRD study equation has been 
shown to be a good way to estimate the GFR in subjects 
with CKD  [9] . However, in other subjects with kidney 
disease, the accuracy and the precision of the equation 
are less impressive. Thus, for hospitalized patients, espe-
cially those in intensive care and in transplantation, all 
formula-based estimates of eGFR are prone to substantial 
error  [27, 30, 31] . This is not only because of reduced ac-
tivity and muscle mass, but also because of day-to-day 
changes in kidney function. In all these patients, the 
MDRD study equation may be misleading.
 MDRD Study Equation in Practice 
 In this review, we have underlined some limitations 
linked to formula-based estimates of the GFR. We agree 
that the MDRD study equation provides a good estimate 
of GFR, specifically in subjects with CKD who are in the 
steady state. We use and recommend that MDRD study 
equation results should be stated by clinical laboratories 
based on the serum creatinine, age, gender, and race, but 
without giving the absolute result when GFR is  1 60 ml/
min/1.73 m 2 . For particular populations, such as subjects 
on chronic dialysis and subjects with acutely changing 
kidney function, the formula-based estimates of GFR are 
false, and should be omitted or ignored. In any case, cur-
rent formula-based estimates of the GFR remain estima-
tions and we must keep this in mind when analyzing their 
results. The use of cystatin C as a new plasma marker of 
cystatin C and of cystatin C-based equations for better 
estimating GFR is increasing but it must be still validated 
before its implementation in daily clinical practice  [32] . 
Table 3. Classification of CKD according the KDOQI guidelines
Estimated GFR
ml/min/1.73 m2
Clinical significance Stage of CKD
≥90 With another abnormality1,
otherwise regard as normal
1
60–89 With another abnormality1,
otherwise regard as normal
2
30–59 Moderate impairment 3
15–29 Severe impairment 4
<15 Advanced renal failure 5
1 Patients with estimated GFR ≥60 ml/min/1.73 m2 should be 
regarded as normal unless they have evidence of kidney disease 
(persistent proteinuria or hematuria, or both, microalbuminuria 
in patients with diabetes, structural kidney disease such as poly-
cystic kidney disease in adults or reflux nephropathy).
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 In this paper, Delanaye and Cohen critically review 
the validity of formulae used to estimate GFR. Their em-
phasis is on the limitations of the most commonly used 
MDRD and Cockcroft-Gault formulae. Their criticism, 
severe at times, reiterates concerns expressed by many 
nephrologists on the accuracy of these formulae for 
screening and detection of CKD within the general pop-
ulation. Clearly, such formulae have serious limitations at 
both spectra of CKD; CKD-1 and -2 as well as CKD-5. 
The authors also review adaptations to the MDRD for-
mula for various non-Caucasian populations. These may 
facilitate the applicability of this formula in a number of 
countries and ethnicities. Finally, it has to be acknowl-
edged that in spite of their limitations, the wide use of 
these formulae, especially amongst non-nephrologists, 
has focused minds on the degree of severity of CKD in a 
number of patients where it may have been overlooked in 
the past. Also, these formulae may open up the way in the 
future for new calculations, some based on serum cys-
tatin C levels and others on a combination of serum cre-
atinine and cystatin C, that may prove more accurate and 
adaptable. 
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